|Dr. Angelos M. Stergiou M.D., ScD h.c.||Founder, Pres, CEO & Director||962.5k||N/A||1976|
|Mr. John Thomas Burns CPA, CPA||VP of Fin. & Corp. Controller & Interim Principal Accounting Officer||338.45k||N/A||1985|
|Ms. Barbara A. Wood||Exec. VP, Gen. Counsel & Sec.||525.49k||N/A||1963|
|Mr. Martin G. Baum||Chief Operating Officer||N/A||N/A||1966|
|Dr. Dragan Cicic||Sr. VP of Clinical Devel.||N/A||N/A||1963|
SELLAS Life Sciences Group, Inc., a clinical-stage biopharmaceutical company, focuses on the development of novel cancer immunotherapies for various cancer indications. The company's lead product candidate is galinpepimut-S (GPS), a wilms tumor 1 targeting peptide-based cancer immunotherapeutic agent, which has entered in Phase III clinical trials for the treatment of acute myeloid leukemia; and is in various development phases as a potential treatment for ovarian cancer. It also develops nelipepimut-S (NPS) that is in Phase 2b clinical trials for the treatment of breast cancer; GALE-301 and GALE-302, which is in Phase 1/2a trials in ovarian and endometrial cancers. The company has strategic collaboration with Merck & Co., Inc. to evaluate GPS as it is administered in combination with PD1 blocker pembrolizumab in a Phase 1/2 clinical trial enrolling patients in up to five cancer indications, including hematologic malignancies and solid tumors; and Advaxis, Inc. on a research program to evaluate, through a proof of principle trial, a clinical candidate, which comprises the combination of proprietary Lm-based antigen delivery technology and GPS. SELLAS Life Sciences Group, Inc. is headquartered in New York, New York.
SELLAS Life Sciences Group, Inc.’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.